top of page


April 7, 2023

Azome Therapeutics, an early stage drug discovery company, announced the appointment of Ulrich H. Von Andrian, MD to its Scientific Advisory Board.  Dr. Von Andrian is the Edward Mallinckrodt Jr. Professor of Immunopathology, Microbiology and Immunobiology at Harvard Medical School, and Senior Investigator at the Von Andrian Lab at Boston Children's Hospital.

March 6, 2023

Azome Therapeutics, an early-stage drug discovery company, announced the execution of an exclusive US patent license.  Under the agreement, Azome acquired exclusive rights to patent US10562935 entitled “Stapled peptides and uses thereof” and related EU patent applications. The intellectual property includes substantial and specific composition of matter and method of use protection for the company’s core RHAMM antagonist technology platform.

January 3, 2023

Azome Therapeutics announced its formation as a Delaware C corporation. The early stage drug discovery company’s founding partners are Elliott Gruskin, PhD (CEO), Amol Karwa, MS (Vice President, R&D), Rashmin Savani, MBChB (Head, Scientific Advisory Board), Eva Turley, PhD and Len Luyt, PhD (Scientific Advisors).

Most recently Gruskin and Karwa were senior R&D executives with Mallinckrodt Pharmaceuticals. Dr. Savani is currently Professor, Nemours Eminent Scholar, and Chair of Pediatrics at the University of Florida College of Medicine in Gainesville. Drs. Turley and Luyt are Professors at the University of Western Ontario in London, Ontario.

The company also named Steven J. Romano, MD as its Non-Executive Chairman of the Board and Stephen Murray, MD PhD as a Scientific Advisor.

bottom of page